Published in Stroke on September 08, 2005
Predictors of Recurrent Stroke in the PROGRESS Study | NCT00049894
Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med (2009) 1.63
Inflammatory mechanisms of stroke. Stroke (2010) 1.06
C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study. Stroke (2014) 0.97
Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol (2006) 0.95
Association of circulating inflammatory markers with recurrent vascular events after stroke: a prospective cohort study. Stroke (2010) 0.88
CD40 ligand as a potential biomarker for atherosclerotic instability. Neurol Res (2013) 0.84
Biomarkers for stroke. J Stroke (2013) 0.83
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet Genomics (2009) 0.78
Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol (2016) 0.77
Significance of inflammatory markers in diabetic patients with stable coronary artery disease. Korean J Intern Med (2009) 0.75
The follow-up of patients of sixty-five years of age and younger with acute ischemic stroke and transient ischemic attacks, and elevated D-dimer levels in plasma. Neurol Int (2009) 0.75
A preliminary method development study to identify potential stroke biomarkers in plasma using multiple chromatographies with nanoLC-ESIMS detection. J Neural Transm (Vienna) (2013) 0.75
Hemostatic Markers and Long-Term Risk of Intracerebral Hemorrhage in Postmenopausal Women. J Stroke Cerebrovasc Dis (2016) 0.75
Hyperfibrinogenemia predicts long-term risk of death after ischemic stroke. J Thromb Thrombolysis (2014) 0.75
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
AMPK in Health and Disease. Physiol Rev (2009) 6.38
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem (2005) 6.27
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet (2005) 5.51
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol (2008) 5.40
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (2012) 5.10
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation (2008) 4.29
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med (2014) 3.81
The ancient drug salicylate directly activates AMP-activated protein kinase. Science (2012) 3.77
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
AMPK is a direct adenylate charge-regulated protein kinase. Science (2011) 3.58
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med (2005) 3.44
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension (2003) 3.29
Lifecourse influences on health among British adults: effects of region of residence in childhood and adulthood. Int J Epidemiol (2007) 3.15
CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med (2006) 3.11
Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab (2008) 3.04
Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med (2003) 3.02
Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation (2005) 2.97
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol (2006) 2.94
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes (2006) 2.80
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes (2003) 2.79
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation (2010) 2.78
Physical activity and hemostatic and inflammatory variables in elderly men. Circulation (2002) 2.75
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet (2006) 2.72
Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control (2008) 2.68
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells (2003) 2.62
C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation (2005) 2.53
Salt reduction initiatives around the world. J Hypertens (2011) 2.44
Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab (2006) 2.43
Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol (2005) 2.42
Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J (2008) 2.41
An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. Hypertension (2010) 2.40
Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens (2006) 2.37
Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest (2011) 2.34
Red cell distribution width and coronary artery bypass surgery. Eur J Cardiothorac Surg (2012) 2.32
β-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc Natl Acad Sci U S A (2010) 2.28
Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. Am J Clin Nutr (2006) 2.24
Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J (2005) 2.21
AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol (2003) 2.19
Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation (2011) 2.17
Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol (2008) 2.14
AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes (2008) 2.13
Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care (2004) 2.11
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care (2013) 2.07
Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology (2012) 2.06
Do acute phase markers explain body temperature and brain temperature after ischemic stroke? Neurology (2012) 2.03
Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation (2005) 2.02
Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med (2008) 2.01
High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation (2009) 2.00
Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J Biol Chem (2003) 1.98
The metabolic syndrome and CVD outcomes for a central Australian cohort. Diabetes Res Clin Pract (2013) 1.97
AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci U S A (2011) 1.96
Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. PLoS Med (2008) 1.95
Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem (2006) 1.93
Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol (2008) 1.93
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med (2013) 1.91
Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension (2011) 1.89
Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation (2005) 1.89
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care (2009) 1.89
Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci (2004) 1.89
Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med (2009) 1.86
Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation (2007) 1.85
Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol (2012) 1.84